Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
What this study shows
The trial that established rapamycin (sirolimus) as an immunosuppressant in kidney transplant patients - its original, still-standard clinical use.
At a glance
| Evidence type | H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H. |
| Study type | 2 - Human Clinical Trial |
| Model system | Humans, phase III RCT (n=719) |
| Journal | Lancet |
| Year | 2000 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1016/S0140-6736(00)02480-6 · PMID 10963197 |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Sirolimus (vs azathioprine; + cyclosporine/prednisone) |
| Target | mTOR |
| Model | Human – phase III RCT (n=719, renal transplant) |
| Effect | Adding sirolimus reduced acute renal allograft rejection compared with azathioprine |
In the Atlas
Related topics
Was this page useful?
Thank you. Your answer was counted anonymously.